Study identifier:D0695L00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomised, double-blind, multi-centre, parallel group study comparing efficacy and safety of 5 mg/ml ropivacaine and 5 mg/ml bupivacaine for spinal anaesthesia in patients undergoing unilateral lower limb surgery
Anesthesia,Spinal
Phase 3
No
Ropivacaine, Bupivacaine
All
220
Interventional
18 Years - 70 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to compare the efficacy, duration of motor block until return to normal function in the non-operated leg after the start of injection, of ropivacaine 5 mg/ml and bupivacaine 5 mg/ml when used for spinal anaesthesia in patients undergoing unilateral lower limb surgery.
Location
Location
Shanghai, China
Location
Beijing, China
Location
Shenyang, China
Location
Xi’an, China
Location
Guangzhou, China
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.